Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP402959.RA6yF94G9ETfw1PuVh9rmP1U7ISnLHKPAxor4zgQYR2UE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP402959.RA6yF94G9ETfw1PuVh9rmP1U7ISnLHKPAxor4zgQYR2UE130_assertion type Assertion NP402959.RA6yF94G9ETfw1PuVh9rmP1U7ISnLHKPAxor4zgQYR2UE130_head.
- NP402959.RA6yF94G9ETfw1PuVh9rmP1U7ISnLHKPAxor4zgQYR2UE130_assertion description "[We used the allelic discrimination method to identify polymorphisms in GSTT1, SULT1C2, CDA, SXR (drug metabolic pathways), XPD, XPA, XPG, ERCC1, TOP2A (DNA repair), VEGF (angiogenesis), and MDR1 (multidrug resistance) genes in 110 adult patients with intermediate-risk AML, enrolled in the CETLAM-99 prospective trial.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP402959.RA6yF94G9ETfw1PuVh9rmP1U7ISnLHKPAxor4zgQYR2UE130_provenance.
- NP402959.RA6yF94G9ETfw1PuVh9rmP1U7ISnLHKPAxor4zgQYR2UE130_assertion evidence source_evidence_literature NP402959.RA6yF94G9ETfw1PuVh9rmP1U7ISnLHKPAxor4zgQYR2UE130_provenance.
- NP402959.RA6yF94G9ETfw1PuVh9rmP1U7ISnLHKPAxor4zgQYR2UE130_assertion SIO_000772 16507781 NP402959.RA6yF94G9ETfw1PuVh9rmP1U7ISnLHKPAxor4zgQYR2UE130_provenance.
- NP402959.RA6yF94G9ETfw1PuVh9rmP1U7ISnLHKPAxor4zgQYR2UE130_assertion wasDerivedFrom befree-20140225 NP402959.RA6yF94G9ETfw1PuVh9rmP1U7ISnLHKPAxor4zgQYR2UE130_provenance.
- NP402959.RA6yF94G9ETfw1PuVh9rmP1U7ISnLHKPAxor4zgQYR2UE130_assertion wasGeneratedBy ECO_0000203 NP402959.RA6yF94G9ETfw1PuVh9rmP1U7ISnLHKPAxor4zgQYR2UE130_provenance.